Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 2.6/5

Cingulate (CING US)

5
Analysis
Health Care • United States
Cingulate Inc. operates as a clinical stage biopharmaceutical company. The Company develops pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
more
bullish•Cingulate
•15 May 2025 17:00•Issuer-paid

CING: First Quarter 2025 Results

Cingulate is developing its Precision Timed Release (PTR) technology to deliver ADHD drugs to improve onset & efficacy of previously approved...

Share
bullish•Cingulate
•10 Apr 2025 14:00•Issuer-paid

CING: 2024 Financial and Operational Results

Cingulate is developing its Precision Timed Release (PTR) technology to deliver ADHD drugs to improve onset & efficacy of previously approved...

Share
bullish•Cingulate
•10 Mar 2025 14:00•Issuer-paid

CING: April Pre-NDA Meeting

Cingulate is developing its Precision Timed Release (PTR) technology to deliver ADHD drugs to improve onset & efficacy of previously approved...

Share
bullish•Cingulate
•12 Nov 2024 15:00•Issuer-paid

CING: Third Quarter Results

Cingulate is developing its Precision Timed Release (PTR) technology to deliver ADHD drugs to improve onset & efficacy of previously approved...

Share
bullish•Cingulate
•26 Aug 2024 14:00•Issuer-paid

CING: Initiating Coverage - Precision Timed Release Delivers Active-Day Coverage

Cingulate is developing its Precision Timed Release (PTR) technology to deliver ADHD drugs to improve onset & efficacy of previously approved...

Share
No more insights
x